SCHEMBL4770018

SCHEMBL4770018

COc1ccc(-c2[nH]c(=O)c3ccccc3c2OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.54
TNKS O95271 3/20 0.54
TNKS2 Q9H2K2 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
GUSB P08236 1/20 0.54
CASP3 P42574 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
SERPINE1 P05121 4/20 0.52
TUBB4A P04350 2/20 0.49
TUBB P07437 2/20 0.49
TUBA3C P0DPH7 2/20 0.49
TUBA1B P68363 2/20 0.49
TUBA4A P68366 2/20 0.49
TUBB4B P68371 2/20 0.49
TUBB3 Q13509 2/20 0.49
TUBB2A Q13885 2/20 0.49
TUBB8 Q3ZCM7 2/20 0.49
TUBA3E Q6PEY2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL853554 0.84 SERPINE1 (0.72) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL29639239 0.84 PTGS2 (0.59) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL854032 0.84 PARP1 (0.62) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL12323935 0.83 PARP1 (0.57) PARP1TNKSTNKS2NPC1RAB9A
Hydrochloric Acid SCHEMBL854206 0.83 PARP1 (0.61) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL12323798 0.79 PARP1 (0.48) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL854577 0.77 POLB (0.51) MAPT
SCHEMBL1150241 0.73 ALDH1A1 (0.52) PARP1TNKSTNKS2NPC1RAB9A
SCHEMBL29639192 0.72 SERPINE1 (0.56) TNKS2SERPINE1TUBB4ATUBBTUBA3C
SCHEMBL28860747 0.71 PARP1 (0.66) PARP1TNKSTNKS2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 PARP1 1660/4885TNKS 2508/4885TNKS2 2823/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 PARP1 1099/4885TNKS 2461/4885TNKS2 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.